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Abstract:
Background: Chronic breathlessness is a neglected symptom of 
advanced diseases. 
Aim: To examine the effect of airflow for chronic breathlessness relief. 
Design: Exploratory systematic review and meta-analysis. 
Data sources: Medline, CINAHL, AMED and Cochrane databases were 
searched (1985  2018) for observational studies or randomised 
controlled trials of airflow as intervention or comparator. Selection 
against pre-defined inclusion criteria, quality-appraisal and data 
extraction were conducted by two independent reviewers with access to 
a third for unresolved differences. Before and after breathlessness 
measures from airflow arms were analysed. Meta-analysis was carried 
out where possible. 
Results: 16/78 studies (n=929) were included; 11 randomised controlled 
trials of oxygen vs medical air, four randomised controlled trials and one 
fan cohort study. Three meta-analyses were possible: i) Fan at rest in 
three studies (n=111) offered significant benefit for breathlessness 
intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating 
Scale), mean difference -11.17 (95% confidence intervals -16.60 to -
5.74), p=0.06 I² 64%.  ii) Medical air via nasal cannulae at rest in two 
studies (n=89) improved breathlessness intensity (visual analogue 
scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
For Peer Review
16.6, P<0.0001 I² =0%. iii) Medical airflow during a constant load 
exercise test before and after rehabilitation (n=29) in two studies 
improved breathlessness intensity (mBorg, 0-10) mean difference -2.9, 
95% confidence intervals -3.2 to -2.7, p<0.0001 I² =0%. 
Conclusion: Airflow appears to offer meaningful relief of chronic 
breathlessness and should be considered as an adjunct treatment in the 
management of breathlessness. 
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Abstract
Background: Chronic breathlessness is a neglected symptom of advanced diseases. 
Aim: To examine the effect of airflow for chronic breathlessness relief. 
Design: Exploratory systematic review and meta-analysis. 
Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985  
2018) for observational studies or randomised controlled trials of airflow as intervention or 
comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data 
extraction were conducted by two independent reviewers with access to a third for unresolved 
differences. Before and after breathlessness measures from airflow arms were analysed. 
Meta-analysis was carried out where possible.
Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs 
medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses 
were possible: i) Fan at rest in three studies (n=111) offered significant benefit for 
breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating 
Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I² 64%.  ii) 
Medical air via nasal cannulae at rest in two studies (n=89) improved breathlessness intensity 
(visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, 
P<0.0001 I² =0%. iii) Medical airflow during a constant load exercise test before and after 
rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean 
difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I² =0%. 
Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should 
be considered as an adjunct treatment in the management of breathlessness. 
Keywords: 
 dyspnea, 
 self-management, 
 review, 
 airflow (relevant term as the intervention subject heading)
Page 3 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
What is already known?
 Randomised Controlled Trials (RCTs) and cohort data have demonstrated that airflow 
delivered from the fan at rest offers significant relief of breathlessness.   
 Systematic review (SR) and RCTs of oxygen vs medical air have failed to 
demonstrate additional benefit from oxygen therapy and suggest that medical air 
delivery, airflow, is likely to be an active intervention.
 All current evidence available for the effect of airflow for chronic breathlessness 
relief has not been explored using SR methods. 
What this paper adds
This exploratory SR and meta-analyses provide promising data to suggest that:
 airflow from the fan at rest improves breathlessness in people with breathlessness due 
to a variety of causes 
 airflow delivered as cylinder medical air at rest improves breathlessness in advanced 
cancer 
 airflow delivered as cylinder medical air during a constant load exercise test in people 
with chronic obstructive pulmonary disease and who have completed pulmonary 
rehabilitation
Implications for practice and theory 
 Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest 
in patients who do not require oxygen-enriched air.
 Airflow may benefit exertion-induced breathlessness, but further work is required to 
investigate the role of the fan with everyday general activity and in relation to 
exercise.
 Recovery time from exertion-induced breathlessness, self-efficacy and daily activity 
are key outcomes to explore in future studies of airflow.
Page 4 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
Introduction
Breathlessness is a common, often poorly managed symptom in people with advanced 
diseases. It is associated with reduced quality of life (1), decreased activities of daily living 
(2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts 
devastating and disabling physical, psychological and social burden on normal daily life for 
the patient, carers and close family members (6-8). Chronic breathlessness, that is, 
breathlessness that persists despite optimal treatment for the underlying pathophysiology and 
causing such disability (9), all too often is left for patients to manage themselves despite a 
developing evidence base for interventions targeted at the breathlessness itself.
Growing evidence supports complex non-pharmacological interventions to reduce the impact 
of the symptom and improve quality of life. (10-12) Components target peripheral and central 
afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-
operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2nd and 3rd 
branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could 
modulate the central perception of breathlessness leading to decreased neural respiratory 
drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods 
secondary analysis of qualitative interview data from three studies found that 80/111 (72%) 
participants experienced benefit when the fan was used in conjunction with other components 
of a complex intervention. (23) Airflow delivered from the fan may offer a valuable 
contribution to the self-management of chronic breathlessness (13, 15, 23), and has been 
identified as a potentially useful strategy in a variety of situations,  e.g. breathlessness crisis 
(24), a component of pulmonary rehabilitation to assist recovery from exercise, or with 
general everyday activities. (15)
Systematic reviews (SR) of oxygen in a variety of non-hypoxic patient groups (cancer, 
chronic heart failure, kyphoscoliosis, COPD and ILD) have not demonstrated additional 
benefit from oxygen therapy over medical air delivery. (25-30) An updated Cochrane review 
of COPD found low quality evidence for modest relief of breathlessness. (31) The results 
from a large, adequately powered trial that randomised 239 participants (COPD 63%, cancer 
16%) to receive at least 15 hours a day of oxygen or medical air delivered via home 
concentrator for seven days reaffirms earlier suggestion that medical air used in the placebo 
arm may not be an inert comparator as previously thought and points to the likelihood of an 
Page 5 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
5
active intervention. (29, 32) Therefore the placebo arm of oxygen studies may provide useful 
preliminary data regarding the role of airflow for the relief of chronic breathlessness. This 
systematic review aims to identify and evaluate data from studies of airflow, both from 
studies of the hand-held fan and the comparator arm data for breathlessness intensity from 
oxygen studies, analysed as before and after airflow exposure cohort data. 
Aim
To examine the current evidence for the effectiveness of airflow for the relief of chronic 
breathlessness. 
Methods
The SR methods employed an exploratory approach in that only the airflow arm of studies 
were used and the data analysed as cohort before and after treatment. 
Study design
The search methods employed are adapted from the Cochrane Handbook of Systematic 
Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA). (34) A review protocol is not pre-registered but 
available from the University of Hull Library (Flavia Swan PhD Thesis).
Inclusion and exclusion criteria 
Types of studies
Randomised Controlled Trials (RCTs), controlled clinical trials (quasi-randomised 
experimental trials with or without blinding) and observational cohort studies were included.
Page 6 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
6
Types of participants
Adults with chronic breathlessness from any advanced disease aetiology as shown below:
 Malignancy: advanced primary and metastatic cancer patients, who have undergone 
disease treatments like chemotherapy, radiotherapy or surgical interventions.
 Chronic Obstructive Pulmonary Disease (COPD) with forced expiratory volume in 1 
second (FEV¹) of less than 50% predicted value
 Interstitial lung disease or pulmonary fibrosis where breathlessness is present
 Chronic heart failure: New York Heart Association (NYHA) stage III-IV
 Motor Neurone disease and other neurological disease where breathlessness is present 
or forced vital capacity (FVC) less than 80% predicted value
 Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine 
Cobb Angle > 50° and FEV¹ of less than 50% predicted value.
Studies were included if at least 50% of the study population were classified as advanced, 
palliative or in the later stages of disease as defined above. These criteria were adapted from 
the Cochrane review of non-pharmacological interventions for breathlessness. (35)
Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for 
Long term Oxygen Therapy (LTOT) (36) were included. Studies of hypoxic participants or 
patients with any condition not assessed as progressive, refractory to treatment and advanced 
such as asthma were excluded.
Types of exposure
Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched 
compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or 
mouthpiece), but not Nasal Intermittent Positive Pressure Ventilation (NIPPV) and ii) 
directed at the cheek of the face, nasal mucosae or mouth. 
Administration: as i) a single dose during ambulation, or at rest taken as needed (PRN pro re 
nata),(37) ii) placebo short-burst oxygen therapy (SBOT) intermittent use before exercise or 
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after exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term 
oxygen therapy (LTOT) studies or during the night as placebo nocturnal oxygen therapy 
(NOT studies) .(38)
Studies where airflow was directly administered to the trachea, or at sub-zero temperatures 
were excluded.
Types of outcome measure
Unidimensional breathlessness outcomes
ATS domains of dyspnea measurement (20) including breathlessness severity or intensity 
rated on uni-dimensional scales  as shown below:
 Modified Borg Score, a categorical scale with ratio properties 
 Visual Analogue Scale (VAS), 0 - 100mm anchored 0 = no shortness of breath 
and 100mm = shortness of breath as bad as can be 
 Numerical Rating Scales (NRS), 0-10 numbered scale anchored 0 = Not 
breathless at all and 10 the worst imaginable breathlessness 
 Likert scales with verbal responses such as a bit better, much better or no 
difference or any other validated uni-dimensional scale for measuring 
breathlessness.
Studies were only included if they reported the breathlessness outcome at baseline and post-
treatment measured as either primary or secondary outcomes. If severity or intensity was 
measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory 
Questionnaire, that unidimensional measure of breathlessness was not extracted and analysed 
separately. Breathlessness related function/quality of life measures were not used as primary 
breathlessness outcomes in the absence of unidimensional scales. 
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Other Outcomes
Other outcomes as shown below measured as either primary or secondary outcomes.
 Participant preference and satisfaction with the treatment
 Participant withdrawal and drop-out from the studies
 Adverse effects recorded
Data sources and searches 
Medline, CINAHL, AMED and Cochrane databases were searched (1985  2015; updated 
January 2018) for observati nal or randomised controlled trials (RCTs) of airflow as 
intervention vs control or as comparator vs oxygen. Reference lists were scanned. A full 
search strategy can be seen in Online Supplementary Table 1.
Study selection
Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria 
by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of 
disagreement. 
Data extraction and synthesis
Baseline and post-intervention measures of breathlessness intensity were extracted from the 
fan studies and from the comparator arm of oxygen studies. Data were analysed as before 
and after airflow exposure cohort observational data. 
Risk of bias
FS and AN judged the reporting quality and internal validity for each of the included studies. 
The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a 
non-randomised study. (39) As there is no tool that is applicable directly to the data extracted 
from the RCTs control arms, we assessed instead the quality of the parent RCTs as a proxy 
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marker for quality data. The RCTs were assessed with the Cochrane Risk of bias tool. (33) 
See online Supplementary Table 2. 
Statistical Analysis
Results from the meta-analyses were reported for the primary outcome, breathlessness 
intensity or severity where heterogeneity allowed, or where not possible these were described 
narratively. NRS and VAS scales were combined by equating one point on a NRS scale to 
10mm on a VAS. (40, 41)
Data calculations for mean difference and SD used STATA Version 12.1, Stata Corp LLC
Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous 
outcomes. Data from the placebo arm of cross-over RCTs were treated as single arm before-
after studies. For studies that recorded median values, the mean were calculated from the 
extracted study data. (42) The I² statistic was used to assess heterogeneity. (43) Where the 
result indicated significant heterogeneity a random effects model was chosen, otherwise a 
fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A 
sensitivity analysis was attempted for any study identified as including a sub-group not fitting 
the review criteria of mild hypo or normoxaemia to assess for any significant difference in 
the breathlessness outcome between the hypoxic and non-hypoxic participants.
Results
A total of 403 records were identified for screening. After removal of duplicates, 78 records 
were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64 
full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion 
criteria and the other 48 studies were excluded (see Figure 1; PRISMA flow chart (34) and 
Online Supplementary Table 3, eAppendix).
Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47% 
men)
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,
Figure 1 PRISMA 2009 Flow-diagram of study selection and retrieval (34)
Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 
1 for study characteristics
Records not relevant and
de-duplication (n=325)
Records identified through database 
searching (n=378) 
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n Additional records identified through 
other sources (n=25) 
(n =   )
            Records total (n=403) 
    After duplicates removed (n=78)
Abstracts included for screening (n=78)
Records excluded (n=14) Reasons: 
abstract poster only (n=3), no 
airflow arm (n=2), opinion piece 
(n=1), hypoxic (n=1), sub-zero 
temperature (n=1), no or incomplete 
dyspnoea outcome (n=5), protocol 
(n=1)
Full-text articles assessed for eligibility 
(n=64)
Full-text articles excluded (n=48) 
Reasons: no or incomplete dyspnoea 
outcome (n =34), hypoxic (n=7), no 
airflow (n=4) insufficient data (n=2), 
sub-zero temperature (n=1),
Studies included in qualitative synthesis 
(n=16)
Studies included in quantitative 
synthesis (meta-analysis) (n=7)
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Description of fan studies
Design: five studies (n=230) used the fan. Two feasibility RCTs; (n =49), (13) and (n=30), 
(44), a feasibility cohort study (n=31), (14), a feasibility longitudinal RCT (n=70), (16) and a 
phase III cross-over RCT (n=50), (17). 
Patient characteristics: Four studies recruited a mixed population of people with 
breathlessness due to a variety of advanced conditions including COPD (n=101), cancer 
(n=55), heart failure (n=23) and other causes (n=21), (13, 14, 16, 17), and one study recruited 
advanced cancer only (n=30). (44) 
Intervention and comparat r characteristics: three studies used the fan to face at rest (14, 
17, 44), two with comparator g oups; fan to leg (17), or no fan use and carer support (44), and 
the other was a cohort design. (14) One study assessed acceptability of the fan when used 
with general activity over 6 months compared with an acupressure wristband (16), and the 
remaining study assessed the fan when used with exercise advice over 4 weeks. (13)
Breathlessness Outcome: Three studies focused on the sensory-perceptual domain of 
dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main 
outcome (14, 44). These studies selected the VAS (17), the NRS (44), or both VAS and NRS 
(14). The other two studies assessed symptom impact as well as the sensory-perceptual 
domain. These studies selected the NRS breathlessness intensity (13) and the Modified Borg 
Scale of breathlessness severity. (16) 
Other outcomes: All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). 
These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no 
Adverse Events (AE) (13) and the other fan studies did not include any AE details. (14, 16, 
17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in one 
study. (14) In addition, one study quantified the experience of fan use at 2 months. (16)
Description of medical air studies
Design: eleven RCTs (n=699) used oxygen, helium hyperoxia or both gases for the 
intervention compared with medical air. (29, 32, 45-53) Study size ranged from 16 to 239 
Page 12 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12
participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a parallel group 
design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and two were 
single blind. (32, 53) 
Patient characteristics: the eleven studies represent; COPD n=537, cancer n=109, other lung 
diseases n=21, cardiac disease n=14 and other causes n=18. Inclusion criteria required 
moderate to severe COPD (45-50, 52, 53), advanced cancer (51), or were a mixed population 
with no specific stipulation of severity. (29, 32)  
Intervention Characteristics: the source of airflow was an oxygen cylinder (32, 45-50), a 
sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source. 
(51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47, 
49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through 
a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute 
(47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute via nasal cannula or 
15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The 
timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or 
6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced 
breathlessness during pulmonary rehabilitation (PR), (46, 52, 53) or a walking test. (47-49) 
The PR programme parameters for airflow delivery were with treadmill exercise 3 times a 
week for 30 minutes over two months (53), a cycle ergometer used 3 times a week for 30 
minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. (52) The 
6MWT test parameters for airflow delivery were; i) three same day 6MWTs with 45 minutes 
washout, using room air for the basal walk and compressed air for the subsequent walks (47), 
ii) five 6MWTs performed over three visits, (timing not stated) using room air for the practice 
walk on visit one and cylinder air for the two 6MWTs with 60 minute washout on visits two 
and three (48), and iii) three same day 6MWTs using cylinder air with 20 minutes washout 
between tests at baseline, 6 and 12 weeks as well as short burst use at home with daily 
activity during the study period. (49)
Breathlessness outcome: two studies focused on the sensory-perceptual domain of dyspnea 
measurement and recorded breathlessness intensity as a primary outcome with the VAS and 
Borg scale (32) or the VAS only. (51) All of the other studies focused on symptom impact as 
well as the sensory-perceptual domain. (29, 45-50, 52, 53) Of these, three studies measured 
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breathlessness intensity as a primary outcome with the NRS (29) or the CRQ dyspnea 
domain. (45, 50) The remaining six studies identified the modified Borg scale as one of the 
main outcomes (47-49, 52, 53) or a secondary measure. (46) One study in addition selected 
the CRQ. (49)
Other outcomes: participant withdrawals were reported in all of the studies (29, 32, 45-51, 
53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the 
other five studies withdrawals ranged from 2 to 21 participants. (45, 53) AE were poorly 
reported with only two studies including details; few or no AE. (29, 46) All of the other 
studies omitted reporting AE. (32, 45, 47-53) Airflow preferences were only reported in one 
study. (51) The remaining studies did not report airflow preferences (29, 32, 45-48, 50, 52, 
53), although one study did quantify side-effects (29) and a second study examined 
preference for cylinder delivery of airflow. (50)
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Table 1 Characteristics of included studies (fan)
Study 
author
Study Design Population Intervention Comparator Mode 
of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, Adverse 
Events (AE), airflow 
preferences
Timing of 
measure
ment
Results airflow arm only 
(before and after 
treatment)
Improvement 
with airflow
Yes/No
Booth 
(2016) [14] 
Feasibility 
observational 
cohort
n= 31 Males: 20
Age mean: 74.8 SD 
11.49 
Mixed population, non-
malignant, 
cardiorespiratory 
disease: 8 (26%)
Baseline dyspnoea 
score:
Mean VAS 48mm SD 
27.4
Hand-held 
fan to face
No 
comparator 
group
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes 
VAS (mm), 
NRS
Withdrawals = 6
AE and airflow 
preferences not 
reported
After 5 
minutes 
at rest
VAS = Mean 35mm SD 
25.7
after 5min air
Mean change = 12mm SD 
21.2
Yes
Bausewein  
(2010) [16]
Feasibility 
longitudinal 
phase II RCT
n = 70 Males: 36 
Age mean: 65.6yrs SD 
8.80 COPD = 45, cancer 
= 25
Baseline dyspnoea 
score: 3.7 (1.83)
Hand-held 
fan to face
Wristband Airflow 
from 
hand-
held 
fan
Modified 
Borg score
Withdrawals at 2 
months =16/33 (48%) 
AE not reported
Airflow preferences: 
Positive = 13/38 
Negative = 7/38 
Monthly 
over 6 
months
Mean Borg score change 
over 2 months = 0.6 (SD 
2.1 ), p = 0.90
No, phase II 
not powered to 
test
Galbraith 
(2010) [17]
Cross-over 
RCT
n = 50 Males: 23
Age mean: 71.3, range 
33-90yrs
Mixed population; COPD 
= 26, lung cancer = 11, 
heart disease = 15
Baseline dyspnoea 
score: 
VAS Fan/face 1st group 
= 31mm (SD 12-61mm) 
Hand-held 
fan to face
Hand-held 
fan to leg
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes
VAS (mm) Withdrawals = 1
AE not reported
Airflow preferences: 
positive patient 
comments, numbers 
not reported
After 5 
minutes 
at rest 
and after 
10 
minute 
washout
VAS = -7.0mm Median 
change after 5 minutes 
Fan/face 1st group (IRQ 
1.5 - 14.5)
VAS = 
-10.0mm Median change 
incl 10 minute washout 
Fan/face 1st group
(IRQ 3.5  17), P=0.003 
Yes
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Table 1 Characteristics of included studies (fan)
Study 
author
Study Design Population Intervention Comparator Mode 
of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results: airflow arm 
only (before and after 
treatment)
Improvement 
with airflow  
Yes/No
Johnson  
(2016) [13]
Feasibility 
phase II RCT
n =49 Males: 26
Age mean: 68 (range 46-
88) 
Mixed population; COPD 
= 28, cancer =9, heart 
disease = 5, others = 7
Baseline dyspnoea score 
Mean NRS = 5.7 (SD 
1.5)
Hand-held 
fan to face at 
high or low 
flow rate
Usual care: 
verbal and 
written 
exercise and 
breathlessne
ss 
management 
advice
Airflow 
from 
hand-
held 
fan
NRS Withdrawals = 6
No AE
Airflow 
preference: 
positive patient 
comments, 
numbers not 
reported
After 4 weeks NRS = 6.0 (2.0) at 4 
weeks
Mean change 0.0 
(3.0)
No, phase II 
not powered to 
test
Wong 
(2017) [44]
Feasibility 
phase II RCT
n=30 Males: 14
Age: NR
Lung cancer = 13, other 
cancers = 17
Baseline dyspnoea score
Control group: NRS 
mean 5.6 (SD 1.55)
Intervention group: NRS 
mean 6.13 (SD 2.48)
Table fan 
with low flow 
rate
Placebo 
accompanie
d by carer 
Airflow 
from 
table 
fan to 
face for 
5 
minutes
NRS No withdrawals
AE not reported
Airflow 
preference: mixed 
patient comments, 
numbers not 
reported
After 5 
minutes at rest
NRS = 4.60 after 5 
minutes fan to face
Mean change -1.53 
(1.06) p< 0.001
Yes
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Table 1 Characteristics of included studies (medical air)
Study author Study 
Design
Population Intervention Comparator Mode of 
gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
arm only (before 
and after 
treatment)
Improvement 
with airflow  
Yes/No
Abernethy 
(2010) [29]
Double-
blind RCT
n = 239 Males: 63%  
Age mean: Air = 74yrs (SD 10)
Mixed: COPD = 152, Primary 
lung cancer = 33
Baseline dyspnoea score: Am 
air = 4.6 (SD 2.4) 
Pm air = 4.7 (SD 2.3)
Oxygen Room air via 
concentrator
2l/min via 
nasal 
cannula for 
at least 
15hrs a 
day (LTOT)
NRS 1-10 Withdrawals = 15
Few AE, number 
not reported
Side-effects 
reported
Airflow 
preferences not 
reported, oxygen 
only
Am and pm 
each day, 
within 30 
minutes of 
waking and 
bedtime for 7 
days
Am = -0.7 NRS 
point change  
Pm = -0.5 NRS 
point change, (p = 
0.5)
Yes
Booth (1996) 
[32]
Single-
blind 
cross-over 
RCT
n = 38 Males: 22
Age Median: 71 Range: 54-
90yrs 
Lung Cancer 20, COPD 13, 
Cardiac 4
Baseline dyspnoea score: VAS 
59mm
Oxygen Cylinder air 4l/minute 
for 15 
minutes via 
nasal 
cannula 
VAS (mm)
Modified 
Borg Scale
No withdrawals
AE and airflow 
preferences not 
reported
After 15 
minutes of 
breathing 
oxygen or air 
at rest.
VAS = -11mm 
change after air 
48mm, p<0.001
Yes
Eaton (2006) 
[45]
Double-
blind 
parallel 
RCT
n = 78 Males: 36 
Age mean: 77.3yrs (7.06) 
Moderate/severe COPD
Baseline CRQ score: Air = 17.5 
(SD 4.2)
Oxygen Cylinder air 2l/minute 
via nasal 
cannula 
over 6 
months
(SBOT)
CRQ Withdrawals = 21
AE and airflow 
preferences not 
reported
Monthly over 6 
months
CRQ = Average 
change over 6 
months: air group 
= -3.6
No
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
comparator arm only 
(before and after 
treatment)
Improvement  
with airflow 
Yes/No
Eves 
(2009) 
[46]
Double-
blind 
RCT
n = 38 Males: 23
Age mean: 65.5yrs (SD 8)
Stable COPD
Baseline dyspnoea score: 
constant load exercise Borg 
mean: Air = 6.0 (SD 2.2)
incremental load exercise Borg 
mean: Air = 5.6 (SD2.0)
Helium-
hyperoxia 
(60% HE: 
40% O²)
Cylinder air Face mask 
(non-
rebreathing)
Modified 
Borg score
No withdrawals
No AE
Airflow 
preferences not 
reported
During 
exercise test 
before and 
after 6 weeks 
pulmonary 
rehabilitation 
programme, 3 
times a week 
for 30 minutes 
on cycle 
ergometer
constant load exercise 
Borg mean: Air = 4.2 
(SD 2.1) mean change 
=  -1.8 (95% CI -3.1 to -
0.2), p < 0.05
incremental load 
exercise Borg mean: 
Air = 5.6 (SD 2.1)
No change (95% CI -
0.7 to 0.7)
Yes
Jolly  
(2001) 
[47]
Double-
blind 
RCT
n = 20 Males: 19
Age mean: 68.5yrs (SEM 2.5)
Stable COPD
Baseline dyspnoea score: Borg 
mean score
Desat group Baseline 6MWT = 
5.82 (SEM 0.46)
Non-desat group Baseline 
6MWT = 4.22 (SEM 0.46)
Oxygen Cylinder air 3l/minute via 
nasal 
cannula
Modified 
Borg score
No withdrawals
AE and airflow 
preferences not 
reported
Before and 
after 3 x 6 
MWTs with at 
least 
45minutes 
washout 
between walks
Borg mean score: 
Desat group 
Air 6MWT = 5.82 (SEM 
0.42) 
No change
Non-desat group 
Air 6MWT = 4.44 (SEM 
0.73)
No change
No
Marciniuk 
(2007) 
[48]
Double-
blind 
crossove
r RCT
n = 16 Males: 7
Age mean: 67 (SD 8)
Moderate to severe COPD
Baseline dyspnoea score: Borg 
mean score Baseline 6MWT = 5 
(SD 2)
100% 
Oxygen or 
Helium-
hyperoxia 
(70% HE: 
30% O²)
Cylinder air 15l/minute 
via face 
mask 
8l/minute via 
nasal 
cannula
Modified 
Borg score
No withdrawals
AE and airflow 
preferences not 
reported
Before and 
after each 6 
MWTs on visit 
1,2 and 3 with 
60 minutes 
washout 
between walks
Borg mean score 
After 6MWT Air = 3.5
mean Borg score 
change = -1.5 decrease
Yes
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of 
gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other outcomes: 
withdrawals, AE, 
airflow preferences
Timing of 
measurement
Results airflow comparator 
arm only (before and after 
treatment)
Improvement   
with airflow 
Yes/No
McDonald 
(1995) 
[49]
Double-
blind 
crossover 
RCT
n = 26 Males: 24
Age mean: 73 (SD 6)
Stable severe COPD
Baseline dyspnoea score 
6MWT: Air group = 3.8 (SD 1.4) 
CRQ = 14 (SD 5)
Oxygen Cylinder air 4l/minut
e via 
nasal 
cannula
Modified 
Borg score
CRQ
Withdrawals = 7
AE and airflow 
preferences not 
reported
After 6 and 12 
weeks of 
home cylinder 
air using 
6MWT 
exercise test 
with 20 minute 
washout 
between walks
Borg Mean score Home 
air: 6MWT with cylinder air 
= 3.8 (SD 1.5)  No change
CRQ score Home air = 17 
(SD 6)3 point change
No with 
6MWT
Yes with 
CRQ
Moore 
(2011) 
[50]
Double-
blind RCT
n = 143 Males: 99
Age mean: 71.8yrs (SD 9.8)  
Range: 43-78 
Stable COPD
Baseline dyspnoea score: Air = 
17.5 (SD 4.9)
 Oxygen Cylinder air 6l/minut
e via 
nasal 
cannula 
at home 
for 12 
weeks 
with 
activity
(SBOT)
CRQ Withdrawals = 4
AE not reported
Airflow preferences 
45% prefer no 
cylinder 
At 4 weeks 
and 12 weeks
Air: 4 weeks = 18.4 
(SD5.8)
12 weeks = 18.4 (SD 5.8) 
Air: CRQ = Mean change 
at 4 and 12 weeks  = 0.9 
Yes
Philip 
(2006) 
[51]
Double-
blind 
cross-over 
RCT
n = 51 Males: 31
Age median: 65  Range: 33-
82yrs
NSCLC = 22, Small cell lung 
cancer = 6, Breast = 8, 
Colorectal = 4 Others = 11
Baseline dyspnoea score: VAS 
median Air 1st = 52mm (range 
23-92) VAS median Air 2nd = 
42mm (range 10-70)
Oxygen Medical Air 4l/minut
e for 15 
minutes 
via 
nasal 
cannula 
VAS (mm) No withdrawals
AE not reported
Airflow preferences: 
Positive: n=15 
(29%)  
Before and 
after 15 
minutes of gas
VAS median After air 1st = 
-3mm change (range -19 to 
7)
VAS median After air 2nd = 
-11.5mm change (range -
20 to 45) 
VAS mean change = -
13.4mm
Yes
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of 
gas delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
comparator arm only 
(before and after 
treatment)
Improvement 
with airflow 
Yes/No
Scorsone 
(2010) 
[52]
Double-
blind RCT
n = 30 Males: 23
Age mean: 67.3yrs (SD 
8.3)
Moderate to severe 
COPD
Baseline dyspnoea 
score:
Before training 
incremental load 
exercise Borg: Air = 7 
(SD 3)
Before training constant 
load exercise Borg: Air 
= 8 (SD 3)
40% Oxygen 
or Helium -
hyperoxia 
(60% HE: 
40% O²)
Humidified 
room air
Mouthpiece 
from a 
Douglas 
bag
Modified 
Borg score
No withdrawals 
AE and airflow 
preferences not 
reported
During exercise 
before and after a 2 
months pulmonary 
rehabilitation 
programme, 3 times 
a week for 20 
minutes on cycle 
ergometer
After training 
incremental load 
exercise Borg: Air = 4 
(SD 2)
After training constant 
load exercise Borg = 5 
(SD 3)
Borg change = -3 point 
decrease both exercise 
tests
Yes
Wadell 
(2001) 
[53]
Single-
blind 
crossover 
RCT
n = 20 Males: 10
Age mean: 67yrs 
Range: 52-73
Stable COPD
Baseline dyspnoea 
median score: 
Test A (Air) At rest; 
Pre-training Borg: Air 
group = 1.5 (0-3) 
Test A (Air) After 
6MWT, Pre-training 
Borg: Air group = 6.5 
(4-9)
Oxygen Air 5l/minute 
via nasal 
cannula
Modified 
Borg score
Withdrawals =2 
AE and patient 
preferences not 
reported
During exercise 
using 2 x 6MWT 
(air/O² or O²/air) 
with 1hour washout 
before and after a 2 
months pulmonary 
rehabilitation 
programme, 3 times 
a week for 30 
minutes on a 
treadmill
Test A (Air) At rest; 
Post-training Borg: Air 
group =
1 (0-3)
Test A (Air) After 
6MWT, Post-training 
Borg: Air group = 6 (1-
7)
Borg change = 
-0.5 point at rest and 
after exercise test
Yes
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Risk of Bias
The quality appraisal is summarised in Online Supplementary Table 2 and described below.
Allocation: all of the studies, apart from one, a cohort design (14), were described as RCTs. It 
was possible to verify the randomisation process in eight studies. (13, 16, 17, 29, 32, 45, 46, 
50). There was insufficient information to determine the risk of allocation bias in the other 
RCTs. (44, 47-49, 51-53)
Blinding: two of the fan studies attempted to blind the participants (16, 17); a placebo 
wristband was used as a comparator (16) and participants were not told if the fan to face or 
fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and 
phase II RCT (13, 14), and the fifth study stated single blinding that could not be verified 
from the methods described. (44) All five were judged high risk of bias due to incomplete 
blinding or limited description. Nine medical air RCTs were described as double blind. (29, 
45-52) All were judged low risk of bias (29, 45, 46, 48-50, 52), apart from one study that was 
unclear due to the lack of detail reported. (51) Two RCTs were single blind (32, 53); one was 
judged low risk of bias (32) and the other was regarded as unclear risk due to the inadequate 
description. (53)
Incomplete outcome data: 13 studies adequately addressed withdrawals and incomplete 
outcome data; these were considered low risk of bias.(13, 14, 17, 29, 32, 46-53) Three studies 
were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two 
lacked description of how any missing data were statistically managed. (44, 45)
Selective Outcome reporting: all of the studies reported the pre-specified outcomes and were 
judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for 
eight studies. (13, 14, 16, 17, 29, 46, 50, 51)
Other issues of bias: twelve studies appeared free from other bias and were judged low risk. 
(13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to 
adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14)
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Effect of interventions
The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either 
intermittently or as periods of continuous flow) whilst the participant continued with usual 
general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced 
breathlessness. (46-49, 52, 53)
i) At rest
Five studies demonstrated improvement with airflow delivery at rest. 
Results from 5 minutes fan use to the face in three studies were VAS breathlessness intensity 
difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and mean -12mm (CI -19.3 to -
4.4) (14), and for the NRS mean change -1.53 (-9.6 to -6.5).(44) 
Cylinder medical air delivery for 15 minutes demonstrated improvement VAS breathlessness 
intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -20.5 to-6.3). (51) Four 
studies were sub-divided into two groups and included in meta-analyses.
Fan
Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% 
cancer) VAS (mm) mean difference (MD), -11.17 (CI -16.60 to -5.74), p=0.06. Significant 
heterogeneity was observed, Chi² p-value = 0.2, (I² = 64%) (See Figure 2). 
<<insert Figure 2 Meta-analysis of fan at rest >>
Medical air
Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer 
(n=89) VAS (mm) MD -12.0, (CI -16.6 to -7.4), P<0.0001. No evidence of heterogeneity was 
observed, Chi² P value = 0.6, (I² =0%).
<<insert Figure 3 Meta-analysis of cylinder air at rest >>
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ii) General activity
Six studies used airflow at home with everyday general activity. A narrative description was 
used for these due to study diversity. Breathlessness points change from four cylinder air 
studies were mixed (29, 45, 49, 50), with CRQ -3.6 after 6 months (45), 3.0 after 12 weeks 
(49), or 0.9 at 12 weeks (50), or NRS  -0.7 (am) and -0.5 NRS (pm) after 7 days. (29) In the 
two fan studies a modified Borg score of -0.6 (SD 2.1) was found after 2 months (16), but 
there was no NRS score change after 4 weeks of fan use with exercise advice. (13)
iii) Exertion-induced breathlessness
Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean 
Borg breathlessness score during a walking test for three studies varied; no change during a 
6MWT repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 for a 
6MWT repeated on 3 separate visits. (48) Airflow delivered during a constant load exercise 
test after PR in three studies also demonstrated variable improvement in mean Borg 
breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle ergometer, and -0.5 
point from a treadmill test. (53) Two studies were suitable to include in a meta-analysis (See 
Figure 4). (46, 52)
Medical air 
Airflow delivered as cylinder medical air during a constant load exercise test after PR in 
COPD (n=29) significantly improved breathlessness Borg score MD -2.9, (CI -3.2 to -2.7), 
p<0.0001. No evidence of heterogeneity was observed, Chi² p-value = 0.7, (I² =0%), (Figure 
4).
<< insert Figure 4 Meta-analysis of cylinder medical air for exertion-induced 
breathlessness>>
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Discussion
These exploratory data support that facial and nasal airflow delivery at rest offers relief of 
breathlessness intensity consistent with a moderate clinically important difference, (54, 55) 
and during exertion. (46, 52) All participants in the cylinder medical air delivery at rest 
studies had advanced cancer, but nearly half of those in the fan at rest studies had other 
conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.  
In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with 
chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) 
However, the data presented here varied with regard to relief of breathlessness intensity when 
facial or nasal airflow delivery was used with everyday general activity or with exertion 
induced breathlessness. This may reflect the use of outcome measures that do not reliably 
capture change in breathlessness intensity in the context of exertion. Studies that used a 
6MWT (47-49) highlight the problem of a self-paced test that allows patients to control their 
walking speed and thus limit the maximal level of exertioninduced breathlessness 
experienced. In contrast, studies that used an externally paced test, such as the cycle 
ergometer, identified relief of breathlessness intensity. (46, 52) The relationship between 
exercise and breathlessness intensity is complex, and measuring one without taking the other 
into account may miss relevant improvement. Scores are likely to remain static after the 
introduction of an intervention as patients are able to exert themselves to the same level of 
breathlessness without noticing an increase in their exercise tolerance (58), or indeed the 
outcome may be of little value to the patient. (57) 
A previous study of recovery time after an ISWT in people with thoracic cancer (n=57) 
reported a rapid reduction in breathlessness intensity with a return to baseline time of median 
4 (IQR 2-5) minutes. (59) The analysis of 133 patient interviews found that a faster recovery 
time was a key patient-reported benefit of airflow delivered from the fan, irrespective of 
breathlessness intensity. (57) Even though recovery time may only be a matter of minutes, 
interventions which shorten this further are clearly welcomed and give the patient a sense of 
self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover 
quickly and predictably from bouts of exertion is likely to encourage further activity and 
prevent the deconditioning cycle.
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The fan therefore seems suitable as a patient-delivered intervention to target the recovery 
time from exertion-induced breathlessness. Preliminary magnetoencephalography (MEG) 
imaging data suggests airflow delivery during recovery from exercise may modulate central 
perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin 
innervated by the 2nd and 3rd branches of the trigeminal nerve and/or stimulation of nasal 
mucosa and upper airway flow receptors are reported to improve breathlessness intensity 
and exercise tolerance (18, 19, 61, 62) and could fool the brain into thinking that the 
respiratory status is adequate. (22) 
Unpleasant respiratory sensations associated with exercise are known to adversely influence 
adherence to an exercise regime. (63) Therefore, use of airflow as part of PR may help the 
problems of low patient attendance and poor maintenance of long term outcomes. (64-67) 
Facial airflow from fan use during a cycle ergometer test in COPD patients resulted in 
significant breathlessness reduction and a longer total exercise time. (68) Likewise, the meta-
analysis result from this SR suggest significant relief of breathlessness when airflow is 
delivered during exercise. These data highlight the potential value of using airflow delivery 
with PR or home based exercise programmes. In addition, intervention preference and AE 
data support the role of the fan in this context as a portable device that is unlikely to harm and 
therefore appropriate for the majority of patients to try.
Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday 
general activity and at rest were not captured in the review data. The lack of signal from the 
results may in part reflect the complexity and the nuances of when, where and how this 
intervention is used by patients. (57) Current breathlessness management is modelled on a 
complex intervention, of which the fan is identified as a valuable therapeutic component 
alongside other interventions and strategies that are tailored to the patients breathlessness 
needs. (11, 69) 
Limitation of methods
Data were analysed as cohort before and after design, and no adjustments were made to 
control for confounding bias. The pre-post comparison increases the potential risk of bias and 
it is possible that results may be influenced by the timing of before and after measures. For 
example, studies of longer duration (up to 6 months) may not be representative of the 
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immediate benefits of airflow, but rather reflect more complex use and mechanism of any 
observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of 
bias was assessed using a tool designed for RCTs therefore it is possible that this assessment 
may not capture potential sources of bias associated with the observational methods used in 
this SR. 
Overall, the qualitative synthesis represents findings from 929 participants the largest to date, 
however the meta-analyses pertain to a small number of participants and only provide a 
preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve 
few studies therefore heterogeneity is difficult to estimate and the accuracy of the I² value is 
less certain. (70) The number of studies that fulfilled the review criteria was restricted by the 
need for baseline breathlessness measures. Some of the included studies (32, 51) did not 
report repeated measurements in a format suitable for meta-analysis necessitating statistical 
assumptions. (42)
Implications for practice and further research
Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in 
those who do not require oxygen-enriched air. Clinicians should consider airflow an 
important intervention to use as part of a breathlessness management programme in 
breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in 
those with COPD may provide a useful intervention during pulmonary rehabilitation where 
breathlessness is a reason for poor adherence.
The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and 
portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time 
from exertion induced breathlessness is an important patient-reported outcome and further 
work is needed to explore the role of airflow in recovery, self-efficacy and increased daily 
activity as part of complex breathlessness intervention programmes including rehabilitation.
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Conclusion
These data support facial or nasal airflow for clinically meaningful relief of breathlessness at 
rest. This SR pulls together the growing evidence to support airflow as an effective self-
management option for people with chronic breathlessness and identifies airflow as an 
intervention for future study. 
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Abstract
Background: Chronic breathlessness is a neglected symptom of advanced diseases. 
Aim: To examine the effect of airflow for chronic breathlessness relief. 
Design: Exploratory systematic review and meta-analysis. 
Data sources: Medline, CINAHL, AMED and Cochrane databases were searched (1985  
2018) for observational studies or randomised controlled trials of airflow as intervention or 
comparator. Selection against pre-defined inclusion criteria, quality-appraisal and data 
extraction were conducted by two independent reviewers with access to a third for unresolved 
differences. Before and after breathlessness measures from airflow arms were analysed. 
Meta-analysis was carried out where possible.
Results: 16/78 studies (n=929) were included; 11 randomised controlled trials of oxygen vs 
medical air, four randomised controlled trials and one fan cohort study. Three meta-analyses 
were possible: i) Fan at rest in three studies (n=111) offered significant benefit for 
breathlessness intensity (0-100mm Visual Analogue Scale and 0- 10 Numerical Rating 
Scale), mean difference -11.17 (95% confidence intervals -16.60 to -5.74), p=0.06 I² 64%.  ii) 
Medical air via nasal cannulae at rest in two studies (n=89) improved breathlessness intensity 
(visual analogue scale), mean difference -12.0mm, 95% confidence intervals -7.4 to -16.6, 
P<0.0001 I² =0%. iii) Medical airflow during a constant load exercise test before and after 
rehabilitation (n=29) in two studies improved breathlessness intensity (mBorg, 0-10) mean 
difference -2.9, 95% confidence intervals -3.2 to -2.7, p<0.0001 I² =0%. 
Conclusion: Airflow appears to offer meaningful relief of chronic breathlessness and should 
be considered as an adjunct treatment in the management of breathlessness. 
Keywords: 
 dyspnea, 
 self-management, 
 review, 
 airflow (relevant term as the intervention subject heading)
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What is already known?
 Randomised Controlled Trials (RCTs) and cohort data have demonstrated that airflow 
delivered from the fan at rest offers significant relief of breathlessness.   
 Systematic review (SR) and RCTs of oxygen vs medical air have failed to 
demonstrate additional benefit from oxygen therapy and suggest that medical air 
delivery, airflow, is likely to be an active intervention.
 All current evidence available for the effect of airflow for chronic breathlessness 
relief has not been explored using SR methods. 
What this paper adds
This exploratory SR and meta-analyses provide promising data to suggest that:
 airflow from the fan at rest improves breathlessness in people with breathlessness due 
to a variety of causes 
 airflow delivered as cylinder medical air at rest improves breathlessness in advanced 
cancer 
 airflow delivered as cylinder medical air during a constant load exercise test in people 
with chronic obstructive pulmonary disease and who have completed pulmonary 
rehabilitation
Implications for practice and theory 
 Clinicians should consider the fan as an adjunct to treatment for breathlessness at rest 
in patients who do not require oxygen-enriched air.
 Airflow may benefit exertion-induced breathlessness, but further work is required to 
investigate the role of the fan with everyday general activity and in relation to 
exercise.
 Recovery time from exertion-induced breathlessness, self-efficacy and daily activity 
are key outcomes to explore in future studies of airflow.
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Introduction
Breathlessness is a common, often poorly managed symptom in people with advanced 
diseases. It is associated with reduced quality of life (1), decreased activities of daily living 
(2), unplanned emergency hospital attendance and admission. (3-5) Breathlessness inflicts 
devastating and disabling physical, psychological and social burden on normal daily life for 
the patient, carers and close family members (6-8). Chronic breathlessness, that is, 
breathlessness that persists despite optimal treatment for the underlying pathophysiology and 
causing such disability (9), all too often is left for patients to manage themselves despite a 
developing evidence base for interventions targeted at the breathlessness itself.
Growing evidence supports complex non-pharmacological interventions to reduce the impact 
of the symptom and improve quality of life. (10-12) Components target peripheral and central 
afferent sources of breathlessness sensation, such as facial airflow delivered by the battery-
operated hand-held fan (fan). (13-17) Cooling of the facial skin innervated by the 2nd and 3rd 
branches of the trigeminal nerve, nasal mucosae or the upper airway flow receptors could 
modulate the central perception of breathlessness leading to decreased neural respiratory 
drive, thereby reducing the sensation of breathlessness. (18-22) A recent multi-methods 
secondary analysis of qualitative interview data from three studies found that 80/111 (72%) 
participants experienced benefit when the fan was used in conjunction with other components 
of a complex intervention. (23) Airflow delivered from the fan may offer a valuable 
contribution to the self-management of chronic breathlessness (13, 15, 23), and has been 
identified as a potentially useful strategy in a variety of situations,  e.g. breathlessness crisis 
(24), a component of pulmonary rehabilitation to assist recovery from exercise, or with 
general everyday activities. (15)
Systematic reviews (SR) of oxygen in a variety of non-hypoxic patient groups (cancer, 
chronic heart failure, kyphoscoliosis, COPD and ILD) have not demonstrated additional 
benefit from oxygen therapy over medical air delivery. (25-30) An updated Cochrane review 
of COPD found low quality evidence for modest relief of breathlessness. (31) The results 
from a large, adequately powered trial that randomised 239 participants (COPD 63%, cancer 
16%) to receive at least 15 hours a day of oxygen or medical air delivered via home 
concentrator for seven days reaffirms earlier suggestion that medical air used in the placebo 
arm may not be an inert comparator as previously thought and points to the likelihood of an 
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active intervention. (29, 32) Therefore the placebo arm of oxygen studies may provide useful 
preliminary data regarding the role of airflow for the relief of chronic breathlessness. This 
systematic review aims to identify and evaluate data from studies of airflow, both from 
studies of the hand-held fan and the comparator arm data for breathlessness intensity from 
oxygen studies, analysed as before and after airflow exposure cohort data. 
Aim
To examine the current evidence for the effectiveness of airflow for the relief of chronic 
breathlessness. 
Methods
The SR methods employed an exploratory approach in that only the airflow arm of studies 
were used and the data analysed as cohort before and after treatment. 
Study design
The search methods employed are adapted from the Cochrane Handbook of Systematic 
Reviews (33) and reported in accordance with the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA). (34) A review protocol is not pre-registered but 
available from the University of Hull Library (Flavia Swan PhD Thesis).
Inclusion and exclusion criteria 
Types of studies
Randomised Controlled Trials (RCTs), controlled clinical trials (quasi-randomised 
experimental trials with or without blinding) and observational cohort studies were included.
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Types of participants
Adults with chronic breathlessness from any advanced disease aetiology as shown below:
 Malignancy: advanced primary and metastatic cancer patients, who have undergone 
disease treatments like chemotherapy, radiotherapy or surgical interventions.
 Chronic Obstructive Pulmonary Disease (COPD) with forced expiratory volume in 1 
second (FEV¹) of less than 50% predicted value
 Interstitial lung disease or pulmonary fibrosis where breathlessness is present
 Chronic heart failure: New York Heart Association (NYHA) stage III-IV
 Motor Neurone disease and other neurological disease where breathlessness is present 
or forced vital capacity (FVC) less than 80% predicted value
 Kyphoscoliosis: a moderate - severe sideways and forwards curvature of the spine 
Cobb Angle > 50° and FEV¹ of less than 50% predicted value.
Studies were included if at least 50% of the study population were classified as advanced, 
palliative or in the later stages of disease as defined above. These criteria were adapted from 
the Cochrane review of non-pharmacological interventions for breathlessness. (35)
Studies of participants with mild hypo or normoxaemia, who do not fore-fill the criteria for 
Long term Oxygen Therapy (LTOT) (36) were included. Studies of hypoxic participants or 
patients with any condition not assessed as progressive, refractory to treatment and advanced 
such as asthma were excluded.
Types of exposure
Airflow: i) delivered from either a fan (hand-held or table) or non-oxygen enriched 
compressed air, or from a non-invasive ventilatory method (nasal cannula, mask or 
mouthpiece), but not Nasal Intermittent Positive Pressure Ventilation (NIPPV) and ii) 
directed at the cheek of the face, nasal mucosae or mouth. 
Administration: as i) a single dose during ambulation, or at rest taken as needed (PRN pro re 
nata),(37) ii) placebo short-burst oxygen therapy (SBOT) intermittent use before exercise or 
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after exercise for recovery (36) or iii) continuously over 15hr a day as placebo long-term 
oxygen therapy (LTOT) studies or during the night as placebo nocturnal oxygen therapy 
(NOT studies) .(38)
Studies where airflow was directly administered to the trachea, or at sub-zero temperatures 
were excluded.
Types of outcome measure
Unidimensional breathlessness outcomes
ATS domains of dyspnea measurement (20) including breathlessness severity or intensity 
rated on uni-dimensional scales  as shown below:
 Modified Borg Score, a categorical scale with ratio properties 
 Visual Analogue Scale (VAS), 0 - 100mm anchored 0 = no shortness of breath 
and 100mm = shortness of breath as bad as can be 
 Numerical Rating Scales (NRS), 0-10 numbered scale anchored 0 = Not 
breathless at all and 10 the worst imaginable breathlessness 
 Likert scales with verbal responses such as a bit better, much better or no 
difference or any other validated uni-dimensional scale for measuring 
breathlessness.
Studies were only included if they reported the breathlessness outcome at baseline and post-
treatment measured as either primary or secondary outcomes. If severity or intensity was 
measured as part of a multi-dimensional or composite scale, e.g. the Chronic Respiratory 
Questionnaire, that unidimensional measure of breathlessness was not extracted and analysed 
separately. Breathlessness related function/quality of life measures were not used as primary 
breathlessness outcomes in the absence of unidimensional scales. 
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Other Outcomes
Other outcomes as shown below measured as either primary or secondary outcomes.
 Participant preference and satisfaction with the treatment
 Participant withdrawal and drop-out from the studies
 Adverse effects recorded
Data sources and searches 
Medline, CINAHL, AMED and Cochrane databases were searched (1985  2015; updated 
January 2018) for observati nal or randomised controlled trials (RCTs) of airflow as 
intervention vs control or as comparator vs oxygen. Reference lists were scanned. A full 
search strategy can be seen in Online Supplementary Table 1.
Study selection
Titles, abstracts (and, where unclear, full papers) were screened against the eligibility criteria 
by two independent reviewers FS and AN, with recourse to MJ as a third reviewer in case of 
disagreement. 
Data extraction and synthesis
Baseline and post-intervention measures of breathlessness intensity were extracted from the 
fan studies and from the comparator arm of oxygen studies. Data were analysed as before 
and after airflow exposure cohort observational data. 
Risk of bias
FS and AN judged the reporting quality and internal validity for each of the included studies. 
The cohort study was evaluated according to the Cochrane guidelines for assessing bias in a 
non-randomised study. (39) As there is no tool that is applicable directly to the data extracted 
from the RCTs control arms, we assessed instead the quality of the parent RCTs as a proxy 
Page 39 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9
marker for quality data. The RCTs were assessed with the Cochrane Risk of bias tool. (33) 
See online Supplementary Table 2. 
Statistical Analysis
Results from the meta-analyses were reported for the primary outcome, breathlessness 
intensity or severity where heterogeneity allowed, or where not possible these were described 
narratively. NRS and VAS scales were combined by equating one point on a NRS scale to 
10mm on a VAS. (40, 41)
Data calculations for mean difference and SD used STATA Version 12.1, Stata Corp LLC
Texas 77845-4512, USA. Breathlessness measurements were analysed as continuous 
outcomes. Data from the placebo arm of cross-over RCTs were treated as single arm before-
after studies. For studies that recorded median values, the mean were calculated from the 
extracted study data. (42) The I² statistic was used to assess heterogeneity. (43) Where the 
result indicated significant heterogeneity a random effects model was chosen, otherwise a 
fixed effects model was applied. All analyses were undertaken on Review Manager 5.5. A 
sensitivity analysis was attempted for any study identified as including a sub-group not fitting 
the review criteria of mild hypo or normoxaemia to assess for any significant difference in 
the breathlessness outcome between the hypoxic and non-hypoxic participants.
Results
A total of 403 records were identified for screening. After removal of duplicates, 78 records 
were reviewed. 14 abstracts were rejected for not meeting inclusion criteria; the remaining 64 
full text articles were assessed for eligibility. Of these, 16 studies met the review inclusion 
criteria and the other 48 studies were excluded (see Figure 1; PRISMA flow chart (34) and 
Online Supplementary Table 3, eAppendix).
Overall studies represented 929 participants (age median 61.5, range 33 to 90 years; 47% 
men)
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,
Figure 1 PRISMA 2009 Flow-diagram of study selection and retrieval (34)
Airflow was delivered by fan (13, 14, 16, 17, 44) or as medical air. (29, 32, 45-53) See Table 
1 for study characteristics
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Description of fan studies
Design: five studies (n=230) used the fan. Two feasibility RCTs; (n =49), (13) and (n=30), 
(44), a feasibility cohort study (n=31), (14), a feasibility longitudinal RCT (n=70), (16) and a 
phase III cross-over RCT (n=50), (17). 
Patient characteristics: Four studies recruited a mixed population of people with 
breathlessness due to a variety of advanced conditions including COPD (n=101), cancer 
(n=55), heart failure (n=23) and other causes (n=21), (13, 14, 16, 17), and one study recruited 
advanced cancer only (n=30). (44) 
Intervention and comparat r characteristics: three studies used the fan to face at rest (14, 
17, 44), two with comparator g oups; fan to leg (17), or no fan use and carer support (44), and 
the other was a cohort design. (14) One study assessed acceptability of the fan when used 
with general activity over 6 months compared with an acupressure wristband (16), and the 
remaining study assessed the fan when used with exercise advice over 4 weeks. (13)
Breathlessness Outcome: Three studies focused on the sensory-perceptual domain of 
dyspnea measurement and used breathlessness intensity as the primary outcome (17) or main 
outcome (14, 44). These studies selected the VAS (17), the NRS (44), or both VAS and NRS 
(14). The other two studies assessed symptom impact as well as the sensory-perceptual 
domain. These studies selected the NRS breathlessness intensity (13) and the Modified Borg 
Scale of breathlessness severity. (16) 
Other outcomes: All of the fan studies reported participant withdrawals (13, 14, 16, 17, 44). 
These ranged from 0 to 6 participants. (13, 14, 44) One study reported that there were no 
Adverse Events (AE) (13) and the other fan studies did not include any AE details. (14, 16, 
17, 44) Airflow preferences were described in four fan studies (13, 16, 17, 44) and not in one 
study. (14) In addition, one study quantified the experience of fan use at 2 months. (16)
Description of medical air studies
Design: eleven RCTs (n=699) used oxygen, helium hyperoxia or both gases for the 
intervention compared with medical air. (29, 32, 45-53) Study size ranged from 16 to 239 
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participants. (29, 48) Four were cross-over (32, 48, 49, 51) and seven used a parallel group 
design. (29, 45-47, 50, 52, 53) Nine studies were double blind (29, 45-52), and two were 
single blind. (32, 53) 
Patient characteristics: the eleven studies represent; COPD n=537, cancer n=109, other lung 
diseases n=21, cardiac disease n=14 and other causes n=18. Inclusion criteria required 
moderate to severe COPD (45-50, 52, 53), advanced cancer (51), or were a mixed population 
with no specific stipulation of severity. (29, 32)  
Intervention Characteristics: the source of airflow was an oxygen cylinder (32, 45-50), a 
sham concentrator (29), and a Douglas bag. (52) Two studies did not state the airflow source. 
(51, 53) Medical air or compressed air was delivered through nasal cannulae (29, 32, 45, 47, 
49-51, 53), face-mask and nasal cannula (48), a non-rebreathing face-mask (46) and through 
a mouthpiece. (52) The flow rates varied widely in the studies; 2l/minute (29, 45), 3l/minute 
(47), 4l/minute (32, 49, 51), 5l/minute (53), 6l/minute (50) and 8l/minute via nasal cannula or 
15l/minute with face mask. (48) Two studies did not report flow rate details. (46, 52) The 
timing of airflow delivery was; 15 minutes at rest (32, 51), with daily activity over 3 (50), or 
6 months (45), 15 hours a day over one week (29), or in conjunction with exertion-induced 
breathlessness during pulmonary rehabilitation (PR), (46, 52, 53) or a walking test. (47-49) 
The PR programme parameters for airflow delivery were with treadmill exercise 3 times a 
week for 30 minutes over two months (53), a cycle ergometer used 3 times a week for 30 
minutes over 6 weeks (46), or 3 times a week for 20 minutes over two months. (52) The 
6MWT test parameters for airflow delivery were; i) three same day 6MWTs with 45 minutes 
washout, using room air for the basal walk and compressed air for the subsequent walks (47), 
ii) five 6MWTs performed over three visits, (timing not stated) using room air for the practice 
walk on visit one and cylinder air for the two 6MWTs with 60 minute washout on visits two 
and three (48), and iii) three same day 6MWTs using cylinder air with 20 minutes washout 
between tests at baseline, 6 and 12 weeks as well as short burst use at home with daily 
activity during the study period. (49)
Breathlessness outcome: two studies focused on the sensory-perceptual domain of dyspnea 
measurement and recorded breathlessness intensity as a primary outcome with the VAS and 
Borg scale (32) or the VAS only. (51) All of the other studies focused on symptom impact as 
well as the sensory-perceptual domain. (29, 45-50, 52, 53) Of these, three studies measured 
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breathlessness intensity as a primary outcome with the NRS (29) or the CRQ dyspnea 
domain. (45, 50) The remaining six studies identified the modified Borg scale as one of the 
main outcomes (47-49, 52, 53) or a secondary measure. (46) One study in addition selected 
the CRQ. (49)
Other outcomes: participant withdrawals were reported in all of the studies (29, 32, 45-51, 
53), apart from one. (52) Five studies reported no withdrawals (32, 46-48, 51) and in the 
other five studies withdrawals ranged from 2 to 21 participants. (45, 53) AE were poorly 
reported with only two studies including details; few or no AE. (29, 46) All of the other 
studies omitted reporting AE. (32, 45, 47-53) Airflow preferences were only reported in one 
study. (51) The remaining studies did not report airflow preferences (29, 32, 45-48, 50, 52, 
53), although one study did quantify side-effects (29) and a second study examined 
preference for cylinder delivery of airflow. (50)
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Table 1 Characteristics of included studies (fan)
Study 
author
Study Design Population Intervention Comparator Mode 
of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, Adverse 
Events (AE), airflow 
preferences
Timing of 
measure
ment
Results airflow arm only 
(before and after 
treatment)
Improvement 
with airflow
Yes/No
Booth 
(2016) [14] 
Feasibility 
observational 
cohort
n= 31 Males: 20
Age mean: 74.8 SD 
11.49 
Mixed population, non-
malignant, 
cardiorespiratory 
disease: 8 (26%)
Baseline dyspnoea 
score:
Mean VAS 48mm SD 
27.4
Hand-held 
fan to face
No 
comparator 
group
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes 
VAS (mm), 
NRS
Withdrawals = 6
AE and airflow 
preferences not 
reported
After 5 
minutes 
at rest
VAS = Mean 35mm SD 
25.7
after 5min air
Mean change = 12mm SD 
21.2
Yes
Bausewein  
(2010) [16]
Feasibility 
longitudinal 
phase II RCT
n = 70 Males: 36 
Age mean: 65.6yrs SD 
8.80 COPD = 45, cancer 
= 25
Baseline dyspnoea 
score: 3.7 (1.83)
Hand-held 
fan to face
Wristband Airflow 
from 
hand-
held 
fan
Modified 
Borg score
Withdrawals at 2 
months =16/33 (48%) 
AE not reported
Airflow preferences: 
Positive = 13/38 
Negative = 7/38 
Monthly 
over 6 
months
Mean Borg score change 
over 2 months = 0.6 (SD 
2.1 ), p = 0.90
No, phase II 
not powered to 
test
Galbraith 
(2010) [17]
Cross-over 
RCT
n = 50 Males: 23
Age mean: 71.3, range 
33-90yrs
Mixed population; COPD 
= 26, lung cancer = 11, 
heart disease = 15
Baseline dyspnoea 
score: 
VAS Fan/face 1st group 
= 31mm (SD 12-61mm) 
Hand-held 
fan to face
Hand-held 
fan to leg
Airflow 
from 
hand-
held 
fan to 
face for 
5 
minutes
VAS (mm) Withdrawals = 1
AE not reported
Airflow preferences: 
positive patient 
comments, numbers 
not reported
After 5 
minutes 
at rest 
and after 
10 
minute 
washout
VAS = -7.0mm Median 
change after 5 minutes 
Fan/face 1st group (IRQ 
1.5 - 14.5)
VAS = 
-10.0mm Median change 
incl 10 minute washout 
Fan/face 1st group
(IRQ 3.5  17), P=0.003 
Yes
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Table 1 Characteristics of included studies (fan)
Study 
author
Study Design Population Intervention Comparator Mode 
of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results: airflow arm 
only (before and after 
treatment)
Improvement 
with airflow  
Yes/No
Johnson  
(2016) [13]
Feasibility 
phase II RCT
n =49 Males: 26
Age mean: 68 (range 46-
88) 
Mixed population; COPD 
= 28, cancer =9, heart 
disease = 5, others = 7
Baseline dyspnoea score 
Mean NRS = 5.7 (SD 
1.5)
Hand-held 
fan to face at 
high or low 
flow rate
Usual care: 
verbal and 
written 
exercise and 
breathlessne
ss 
management 
advice
Airflow 
from 
hand-
held 
fan
NRS Withdrawals = 6
No AE
Airflow 
preference: 
positive patient 
comments, 
numbers not 
reported
After 4 weeks NRS = 6.0 (2.0) at 4 
weeks
Mean change 0.0 
(3.0)
No, phase II 
not powered to 
test
Wong 
(2017) [44]
Feasibility 
phase II RCT
n=30 Males: 14
Age: NR
Lung cancer = 13, other 
cancers = 17
Baseline dyspnoea score
Control group: NRS 
mean 5.6 (SD 1.55)
Intervention group: NRS 
mean 6.13 (SD 2.48)
Table fan 
with low flow 
rate
Placebo 
accompanie
d by carer 
Airflow 
from 
table 
fan to 
face for 
5 
minutes
NRS No withdrawals
AE not reported
Airflow 
preference: mixed 
patient comments, 
numbers not 
reported
After 5 
minutes at rest
NRS = 4.60 after 5 
minutes fan to face
Mean change -1.53 
(1.06) p< 0.001
Yes
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Table 1 Characteristics of included studies (medical air)
Study author Study 
Design
Population Intervention Comparator Mode of 
gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
arm only (before 
and after 
treatment)
Improvement 
with airflow  
Yes/No
Abernethy 
(2010) [29]
Double-
blind RCT
n = 239 Males: 63%  
Age mean: Air = 74yrs (SD 10)
Mixed: COPD = 152, Primary 
lung cancer = 33
Baseline dyspnoea score: Am 
air = 4.6 (SD 2.4) 
Pm air = 4.7 (SD 2.3)
Oxygen Room air via 
concentrator
2l/min via 
nasal 
cannula for 
at least 
15hrs a 
day (LTOT)
NRS 1-10 Withdrawals = 15
Few AE, number 
not reported
Side-effects 
reported
Airflow 
preferences not 
reported, oxygen 
only
Am and pm 
each day, 
within 30 
minutes of 
waking and 
bedtime for 7 
days
Am = -0.7 NRS 
point change  
Pm = -0.5 NRS 
point change, (p = 
0.5)
Yes
Booth (1996) 
[32]
Single-
blind 
cross-over 
RCT
n = 38 Males: 22
Age Median: 71 Range: 54-
90yrs 
Lung Cancer 20, COPD 13, 
Cardiac 4
Baseline dyspnoea score: VAS 
59mm
Oxygen Cylinder air 4l/minute 
for 15 
minutes via 
nasal 
cannula 
VAS (mm)
Modified 
Borg Scale
No withdrawals
AE and airflow 
preferences not 
reported
After 15 
minutes of 
breathing 
oxygen or air 
at rest.
VAS = -11mm 
change after air 
48mm, p<0.001
Yes
Eaton (2006) 
[45]
Double-
blind 
parallel 
RCT
n = 78 Males: 36 
Age mean: 77.3yrs (7.06) 
Moderate/severe COPD
Baseline CRQ score: Air = 17.5 
(SD 4.2)
Oxygen Cylinder air 2l/minute 
via nasal 
cannula 
over 6 
months
(SBOT)
CRQ Withdrawals = 21
AE and airflow 
preferences not 
reported
Monthly over 6 
months
CRQ = Average 
change over 6 
months: air group 
= -3.6
No
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
comparator arm only 
(before and after 
treatment)
Improvement  
with airflow 
Yes/No
Eves 
(2009) 
[46]
Double-
blind 
RCT
n = 38 Males: 23
Age mean: 65.5yrs (SD 8)
Stable COPD
Baseline dyspnoea score: 
constant load exercise Borg 
mean: Air = 6.0 (SD 2.2)
incremental load exercise Borg 
mean: Air = 5.6 (SD2.0)
Helium-
hyperoxia 
(60% HE: 
40% O²)
Cylinder air Face mask 
(non-
rebreathing)
Modified 
Borg score
No withdrawals
No AE
Airflow 
preferences not 
reported
During 
exercise test 
before and 
after 6 weeks 
pulmonary 
rehabilitation 
programme, 3 
times a week 
for 30 minutes 
on cycle 
ergometer
constant load exercise 
Borg mean: Air = 4.2 
(SD 2.1) mean change 
=  -1.8 (95% CI -3.1 to -
0.2), p < 0.05
incremental load 
exercise Borg mean: 
Air = 5.6 (SD 2.1)
No change (95% CI -
0.7 to 0.7)
Yes
Jolly  
(2001) 
[47]
Double-
blind 
RCT
n = 20 Males: 19
Age mean: 68.5yrs (SEM 2.5)
Stable COPD
Baseline dyspnoea score: Borg 
mean score
Desat group Baseline 6MWT = 
5.82 (SEM 0.46)
Non-desat group Baseline 
6MWT = 4.22 (SEM 0.46)
Oxygen Cylinder air 3l/minute via 
nasal 
cannula
Modified 
Borg score
No withdrawals
AE and airflow 
preferences not 
reported
Before and 
after 3 x 6 
MWTs with at 
least 
45minutes 
washout 
between walks
Borg mean score: 
Desat group 
Air 6MWT = 5.82 (SEM 
0.42) 
No change
Non-desat group 
Air 6MWT = 4.44 (SEM 
0.73)
No change
No
Marciniuk 
(2007) 
[48]
Double-
blind 
crossove
r RCT
n = 16 Males: 7
Age mean: 67 (SD 8)
Moderate to severe COPD
Baseline dyspnoea score: Borg 
mean score Baseline 6MWT = 5 
(SD 2)
100% 
Oxygen or 
Helium-
hyperoxia 
(70% HE: 
30% O²)
Cylinder air 15l/minute 
via face 
mask 
8l/minute via 
nasal 
cannula
Modified 
Borg score
No withdrawals
AE and airflow 
preferences not 
reported
Before and 
after each 6 
MWTs on visit 
1,2 and 3 with 
60 minutes 
washout 
between walks
Borg mean score 
After 6MWT Air = 3.5
mean Borg score 
change = -1.5 decrease
Yes
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of 
gas 
delivery
Dyspnea 
Outcome 
measure(s)
Other outcomes: 
withdrawals, AE, 
airflow preferences
Timing of 
measurement
Results airflow comparator 
arm only (before and after 
treatment)
Improvement   
with airflow 
Yes/No
McDonald 
(1995) 
[49]
Double-
blind 
crossover 
RCT
n = 26 Males: 24
Age mean: 73 (SD 6)
Stable severe COPD
Baseline dyspnoea score 
6MWT: Air group = 3.8 (SD 1.4) 
CRQ = 14 (SD 5)
Oxygen Cylinder air 4l/minut
e via 
nasal 
cannula
Modified 
Borg score
CRQ
Withdrawals = 7
AE and airflow 
preferences not 
reported
After 6 and 12 
weeks of 
home cylinder 
air using 
6MWT 
exercise test 
with 20 minute 
washout 
between walks
Borg Mean score Home 
air: 6MWT with cylinder air 
= 3.8 (SD 1.5)  No change
CRQ score Home air = 17 
(SD 6)3 point change
No with 
6MWT
Yes with 
CRQ
Moore 
(2011) 
[50]
Double-
blind RCT
n = 143 Males: 99
Age mean: 71.8yrs (SD 9.8)  
Range: 43-78 
Stable COPD
Baseline dyspnoea score: Air = 
17.5 (SD 4.9)
 Oxygen Cylinder air 6l/minut
e via 
nasal 
cannula 
at home 
for 12 
weeks 
with 
activity
(SBOT)
CRQ Withdrawals = 4
AE not reported
Airflow preferences 
45% prefer no 
cylinder 
At 4 weeks 
and 12 weeks
Air: 4 weeks = 18.4 
(SD5.8)
12 weeks = 18.4 (SD 5.8) 
Air: CRQ = Mean change 
at 4 and 12 weeks  = 0.9 
Yes
Philip 
(2006) 
[51]
Double-
blind 
cross-over 
RCT
n = 51 Males: 31
Age median: 65  Range: 33-
82yrs
NSCLC = 22, Small cell lung 
cancer = 6, Breast = 8, 
Colorectal = 4 Others = 11
Baseline dyspnoea score: VAS 
median Air 1st = 52mm (range 
23-92) VAS median Air 2nd = 
42mm (range 10-70)
Oxygen Medical Air 4l/minut
e for 15 
minutes 
via 
nasal 
cannula 
VAS (mm) No withdrawals
AE not reported
Airflow preferences: 
Positive: n=15 
(29%)  
Before and 
after 15 
minutes of gas
VAS median After air 1st = 
-3mm change (range -19 to 
7)
VAS median After air 2nd = 
-11.5mm change (range -
20 to 45) 
VAS mean change = -
13.4mm
Yes
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Table 1 Characteristics of included studies (medical air)
Study 
author
Study 
Design
Population Intervention Comparator Mode of 
gas delivery
Dyspnea 
Outcome 
measure(s)
Other Outcomes: 
withdrawals, AE, 
airflow 
preferences
Timing of 
measurement
Results airflow 
comparator arm only 
(before and after 
treatment)
Improvement 
with airflow 
Yes/No
Scorsone 
(2010) 
[52]
Double-
blind RCT
n = 30 Males: 23
Age mean: 67.3yrs (SD 
8.3)
Moderate to severe 
COPD
Baseline dyspnoea 
score:
Before training 
incremental load 
exercise Borg: Air = 7 
(SD 3)
Before training constant 
load exercise Borg: Air 
= 8 (SD 3)
40% Oxygen 
or Helium -
hyperoxia 
(60% HE: 
40% O²)
Humidified 
room air
Mouthpiece 
from a 
Douglas 
bag
Modified 
Borg score
No withdrawals 
AE and airflow 
preferences not 
reported
During exercise 
before and after a 2 
months pulmonary 
rehabilitation 
programme, 3 times 
a week for 20 
minutes on cycle 
ergometer
After training 
incremental load 
exercise Borg: Air = 4 
(SD 2)
After training constant 
load exercise Borg = 5 
(SD 3)
Borg change = -3 point 
decrease both exercise 
tests
Yes
Wadell 
(2001) 
[53]
Single-
blind 
crossover 
RCT
n = 20 Males: 10
Age mean: 67yrs 
Range: 52-73
Stable COPD
Baseline dyspnoea 
median score: 
Test A (Air) At rest; 
Pre-training Borg: Air 
group = 1.5 (0-3) 
Test A (Air) After 
6MWT, Pre-training 
Borg: Air group = 6.5 
(4-9)
Oxygen Air 5l/minute 
via nasal 
cannula
Modified 
Borg score
Withdrawals =2 
AE and patient 
preferences not 
reported
During exercise 
using 2 x 6MWT 
(air/O² or O²/air) 
with 1hour washout 
before and after a 2 
months pulmonary 
rehabilitation 
programme, 3 times 
a week for 30 
minutes on a 
treadmill
Test A (Air) At rest; 
Post-training Borg: Air 
group =
1 (0-3)
Test A (Air) After 
6MWT, Post-training 
Borg: Air group = 6 (1-
7)
Borg change = 
-0.5 point at rest and 
after exercise test
Yes
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Risk of Bias
The quality appraisal is summarised in Online Supplementary Table 2 and described below.
Allocation: all of the studies, apart from one, a cohort design (14), were described as RCTs. It 
was possible to verify the randomisation process in eight studies. (13, 16, 17, 29, 32, 45, 46, 
50). There was insufficient information to determine the risk of allocation bias in the other 
RCTs. (44, 47-49, 51-53)
Blinding: two of the fan studies attempted to blind the participants (16, 17); a placebo 
wristband was used as a comparator (16) and participants were not told if the fan to face or 
fan to leg was the active intervention. (17) There was no blinding in two studies, a cohort and 
phase II RCT (13, 14), and the fifth study stated single blinding that could not be verified 
from the methods described. (44) All five were judged high risk of bias due to incomplete 
blinding or limited description. Nine medical air RCTs were described as double blind. (29, 
45-52) All were judged low risk of bias (29, 45, 46, 48-50, 52), apart from one study that was 
unclear due to the lack of detail reported. (51) Two RCTs were single blind (32, 53); one was 
judged low risk of bias (32) and the other was regarded as unclear risk due to the inadequate 
description. (53)
Incomplete outcome data: 13 studies adequately addressed withdrawals and incomplete 
outcome data; these were considered low risk of bias.(13, 14, 17, 29, 32, 46-53) Three studies 
were uncertain risk (16, 45); one due to the proportion of attrition (16) and the other two 
lacked description of how any missing data were statistically managed. (44, 45)
Selective Outcome reporting: all of the studies reported the pre-specified outcomes and were 
judged as low risk of bias. (13, 14, 16, 17, 29, 32, 44-53) Study protocols were available for 
eight studies. (13, 14, 16, 17, 29, 46, 50, 51)
Other issues of bias: twelve studies appeared free from other bias and were judged low risk. 
(13, 16, 17, 29, 44-46, 48, 50-53) Three studies reported insufficient information to 
adequately assess risk (32, 47, 49), and one study, a cohort design was judged high risk. (14)
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Effect of interventions
The airflow was delivered, i) at rest (14, 17, 32, 44, 51) ii) over days or weeks (either 
intermittently or as periods of continuous flow) whilst the participant continued with usual 
general activities (13, 16, 29, 45, 50) or iii) during specific episodes of exertion induced 
breathlessness. (46-49, 52, 53)
i) At rest
Five studies demonstrated improvement with airflow delivery at rest. 
Results from 5 minutes fan use to the face in three studies were VAS breathlessness intensity 
difference from baseline mean -7mm (CI -11.5 to -2.5) (17), and mean -12mm (CI -19.3 to -
4.4) (14), and for the NRS mean change -1.53 (-9.6 to -6.5).(44) 
Cylinder medical air delivery for 15 minutes demonstrated improvement VAS breathlessness 
intensity mean -11mm (CI -17.0 to -5.0) (32), and mean -13mm (CI -20.5 to-6.3). (51) Four 
studies were sub-divided into two groups and included in meta-analyses.
Fan
Airflow from the fan at rest improved breathlessness in a mixed population (n=111; 58% 
cancer) VAS (mm) mean difference (MD), -11.17 (CI -16.60 to -5.74), p=0.06. Significant 
heterogeneity was observed, Chi² p-value = 0.2, (I² = 64%) (See Figure 2). 
<<insert Figure 2 Meta-analysis of fan at rest >>
Medical air
Airflow delivered as cylinder medical air at rest improved breathlessness in advanced cancer 
(n=89) VAS (mm) MD -12.0, (CI -16.6 to -7.4), P<0.0001. No evidence of heterogeneity was 
observed, Chi² P value = 0.6, (I² =0%).
<<insert Figure 3 Meta-analysis of cylinder air at rest >>
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ii) General activity
Six studies used airflow at home with everyday general activity. A narrative description was 
used for these due to study diversity. Breathlessness points change from four cylinder air 
studies were mixed (29, 45, 49, 50), with CRQ -3.6 after 6 months (45), 3.0 after 12 weeks 
(49), or 0.9 at 12 weeks (50), or NRS  -0.7 (am) and -0.5 NRS (pm) after 7 days. (29) In the 
two fan studies a modified Borg score of -0.6 (SD 2.1) was found after 2 months (16), but 
there was no NRS score change after 4 weeks of fan use with exercise advice. (13)
iii) Exertion-induced breathlessness
Six studies examined airflow delivery with exertion-induced breathlessness. Results for mean 
Borg breathlessness score during a walking test for three studies varied; no change during a 
6MWT repeated on the same day (47), or at 12 weeks (49), and improvement -1.5 for a 
6MWT repeated on 3 separate visits. (48) Airflow delivered during a constant load exercise 
test after PR in three studies also demonstrated variable improvement in mean Borg 
breathlessness scores; -1.8 points (46), and -3 point (52) using a cycle ergometer, and -0.5 
point from a treadmill test. (53) Two studies were suitable to include in a meta-analysis (See 
Figure 4). (46, 52)
Medical air 
Airflow delivered as cylinder medical air during a constant load exercise test after PR in 
COPD (n=29) significantly improved breathlessness Borg score MD -2.9, (CI -3.2 to -2.7), 
p<0.0001. No evidence of heterogeneity was observed, Chi² p-value = 0.7, (I² =0%), (Figure 
4).
<< insert Figure 4 Meta-analysis of cylinder medical air for exertion-induced 
breathlessness>>
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Discussion
These exploratory data support that facial and nasal airflow delivery at rest offers relief of 
breathlessness intensity consistent with a moderate clinically important difference, (54, 55) 
and during exertion. (46, 52) All participants in the cylinder medical air delivery at rest 
studies had advanced cancer, but nearly half of those in the fan at rest studies had other 
conditions indicating that airflow for breathlessness at rest is of benefit irrespective of cause.  
In a recent pooled qualitative data study of facial airflow use from the fan in 133 people with 
chronic breathlessness (56), over 80% patients reported some or substantial benefit.(57) 
However, the data presented here varied with regard to relief of breathlessness intensity when 
facial or nasal airflow delivery was used with everyday general activity or with exertion 
induced breathlessness. This may reflect the use of outcome measures that do not reliably 
capture change in breathlessness intensity in the context of exertion. Studies that used a 
6MWT (47-49) highlight the problem of a self-paced test that allows patients to control their 
walking speed and thus limit the maximal level of exertioninduced breathlessness 
experienced. In contrast, studies that used an externally paced test, such as the cycle 
ergometer, identified relief of breathlessness intensity. (46, 52) The relationship between 
exercise and breathlessness intensity is complex, and measuring one without taking the other 
into account may miss relevant improvement. Scores are likely to remain static after the 
introduction of an intervention as patients are able to exert themselves to the same level of 
breathlessness without noticing an increase in their exercise tolerance (58), or indeed the 
outcome may be of little value to the patient. (57) 
A previous study of recovery time after an ISWT in people with thoracic cancer (n=57) 
reported a rapid reduction in breathlessness intensity with a return to baseline time of median 
4 (IQR 2-5) minutes. (59) The analysis of 133 patient interviews found that a faster recovery 
time was a key patient-reported benefit of airflow delivered from the fan, irrespective of 
breathlessness intensity. (57) Even though recovery time may only be a matter of minutes, 
interventions which shorten this further are clearly welcomed and give the patient a sense of 
self-control that may help prevent a breathlessness-anxiety spiral. The ability to recover 
quickly and predictably from bouts of exertion is likely to encourage further activity and 
prevent the deconditioning cycle.
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The fan therefore seems suitable as a patient-delivered intervention to target the recovery 
time from exertion-induced breathlessness. Preliminary magnetoencephalography (MEG) 
imaging data suggests airflow delivery during recovery from exercise may modulate central 
perception of breathlessness by modifying sensory attention. (60) Cooling of the facial skin 
innervated by the 2nd and 3rd branches of the trigeminal nerve and/or stimulation of nasal 
mucosa and upper airway flow receptors are reported to improve breathlessness intensity 
and exercise tolerance (18, 19, 61, 62) and could fool the brain into thinking that the 
respiratory status is adequate. (22) 
Unpleasant respiratory sensations associated with exercise are known to adversely influence 
adherence to an exercise regime. (63) Therefore, use of airflow as part of PR may help the 
problems of low patient attendance and poor maintenance of long term outcomes. (64-67) 
Facial airflow from fan use during a cycle ergometer test in COPD patients resulted in 
significant breathlessness reduction and a longer total exercise time. (68) Likewise, the meta-
analysis result from this SR suggest significant relief of breathlessness when airflow is 
delivered during exercise. These data highlight the potential value of using airflow delivery 
with PR or home based exercise programmes. In addition, intervention preference and AE 
data support the role of the fan in this context as a portable device that is unlikely to harm and 
therefore appropriate for the majority of patients to try.
Finally, it is likely that any positive benefits of airflow delivery from fan use with everyday 
general activity and at rest were not captured in the review data. The lack of signal from the 
results may in part reflect the complexity and the nuances of when, where and how this 
intervention is used by patients. (57) Current breathlessness management is modelled on a 
complex intervention, of which the fan is identified as a valuable therapeutic component 
alongside other interventions and strategies that are tailored to the patients breathlessness 
needs. (11, 69) 
Limitation of methods
Data were analysed as cohort before and after design, and no adjustments were made to 
control for confounding bias. The pre-post comparison increases the potential risk of bias and 
it is possible that results may be influenced by the timing of before and after measures. For 
example, studies of longer duration (up to 6 months) may not be representative of the 
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immediate benefits of airflow, but rather reflect more complex use and mechanism of any 
observed benefit may be related to reconditioning, facilitated by airflow, over time. Risk of 
bias was assessed using a tool designed for RCTs therefore it is possible that this assessment 
may not capture potential sources of bias associated with the observational methods used in 
this SR. 
Overall, the qualitative synthesis represents findings from 929 participants the largest to date, 
however the meta-analyses pertain to a small number of participants and only provide a 
preliminary indication of the pooled effect estimate of airflow. The meta-analyses involve 
few studies therefore heterogeneity is difficult to estimate and the accuracy of the I² value is 
less certain. (70) The number of studies that fulfilled the review criteria was restricted by the 
need for baseline breathlessness measures. Some of the included studies (32, 51) did not 
report repeated measurements in a format suitable for meta-analysis necessitating statistical 
assumptions. (42)
Implications for practice and further research
Airflow is safe and should be used as an adjunct to treatment for breathlessness at rest in 
those who do not require oxygen-enriched air. Clinicians should consider airflow an 
important intervention to use as part of a breathlessness management programme in 
breathlessness at rest irrespective of cause. The relief of breathlessness during exertion in 
those with COPD may provide a useful intervention during pulmonary rehabilitation where 
breathlessness is a reason for poor adherence.
The fan, when taught by an appropriately trained clinician, offers patients an inexpensive and 
portable source of airflow likely to benefit exertion-induced breathlessness. Recovery time 
from exertion induced breathlessness is an important patient-reported outcome and further 
work is needed to explore the role of airflow in recovery, self-efficacy and increased daily 
activity as part of complex breathlessness intervention programmes including rehabilitation.
Page 56 of 80
http://mc.http://mc.manuscriptcentral.com/palliative-medicine
Palliative Medicine
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
26
Conclusion
These data support facial or nasal airflow for clinically meaningful relief of breathlessness at 
rest. This SR pulls together the growing evidence to support airflow as an effective self-
management option for people with chronic breathlessness and identifies airflow as an 
intervention for future study. 
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Figure 2 Meta-analysis of fan at rest 
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Figure 3 Meta-analysis of cylinder air at rest 
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Figure 4 Meta-analysis of cylinder medical air for exertion-induced breathlessness 
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